索拉非尼联合或不联合其他干预措施治疗肝细胞癌。
Sorafenib with or without co-interventions for hepatocellular carcinoma.
作者信息
Chen Shanshan, Liu Jian Ping, Li Xinyu, Dang Shoutao, Li Wei
机构信息
Cancer Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
出版信息
Cochrane Database Syst Rev. 2025 Jun 26;6(6):CD015851. doi: 10.1002/14651858.CD015851.
Abstract
This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the beneficial and harmful effects of sorafenib, with or without co-interventions, versus placebo, no intervention, or the same co-interventions for adults, aged 18 and over, with hepatocellular carcinoma.
摘要
这是一项Cochrane系统评价（干预措施）的方案。目标如下：评估索拉非尼（无论是否联合其他干预措施）与安慰剂、不进行干预或相同的联合干预措施相比，对18岁及以上成年肝细胞癌患者的有益和有害影响。
相似文献
1
Sorafenib with or without co-interventions for hepatocellular carcinoma.索拉非尼联合或不联合其他干预措施治疗肝细胞癌。
Cochrane Database Syst Rev. 2025 Jun 26;6(6):CD015851. doi: 10.1002/14651858.CD015851.
2
Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis.中期肝细胞癌患者的管理：一项网络荟萃分析尝试
Cochrane Database Syst Rev. 2017 Mar 10;3(3):CD011649. doi: 10.1002/14651858.CD011649.pub2.
3
Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.钇-90微球放射性栓塞治疗不可切除的肝细胞癌
Cochrane Database Syst Rev. 2016 Feb 16;2:CD011313. doi: 10.1002/14651858.CD011313.pub2.
4
Tamoxifen for adults with hepatocellular carcinoma.他莫昔芬治疗肝细胞癌成人患者。
Cochrane Database Syst Rev. 2024 Aug 12;8(8):CD014869. doi: 10.1002/14651858.CD014869.pub2.
5
Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma.经皮乙醇注射或经皮乙酸注射治疗早期肝细胞癌。
Cochrane Database Syst Rev. 2015 Jan 26;1(1):CD006745. doi: 10.1002/14651858.CD006745.pub3.
6
Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma.射频（热）消融术与不干预或其他干预措施治疗肝细胞癌的比较
Cochrane Database Syst Rev. 2013 Dec 19;2013(12):CD003046. doi: 10.1002/14651858.CD003046.pub3.
7
Management of people with early- or very early-stage hepatocellular carcinoma: an attempted network meta-analysis.早期或极早期肝细胞癌患者的管理：一项网络荟萃分析尝试
Cochrane Database Syst Rev. 2017 Mar 28;3(3):CD011650. doi: 10.1002/14651858.CD011650.pub2.
8
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial.托法替布联合贝伐珠单抗对比索拉非尼作为晚期肝细胞癌一线治疗的疗效（HEPATORCH）：一项随机、开放标签的3期试验
Lancet Gastroenterol Hepatol. 2025 Jul;10(7):658-670. doi: 10.1016/S2468-1253(25)00059-7. Epub 2025 May 20.
9
Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma: The NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical Trial.立体定向体部放射治疗与索拉非尼单药治疗肝细胞癌的疗效比较：NRG肿瘤学/RTOG 1112 3期随机临床试验
JAMA Oncol. 2025 Feb 1;11(2):136-144. doi: 10.1001/jamaoncol.2024.5403.
10
Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review.索拉非尼治疗晚期肝细胞癌患者的疗效：一项系统评价。
Hepatobiliary Pancreat Dis Int. 2012 Oct;11(5):458-66. doi: 10.1016/s1499-3872(12)60209-4.
本文引用的文献
1
Next-Generation Flexible Embolic Systems: Targeted Transarterial Chemoembolization Strategies for Hepatocellular Carcinoma.下一代柔性栓塞系统：肝细胞癌的靶向经动脉化疗栓塞策略
Adv Mater. 2025 Jun;37(24):e2503971. doi: 10.1002/adma.202503971. Epub 2025 Apr 7.
2
Breaking bottlenecks: the future of hepatocellular carcinoma clinical trials and therapeutic targets.突破瓶颈：肝细胞癌临床试验与治疗靶点的未来
Hepatol Int. 2025 Mar 29. doi: 10.1007/s12072-025-10799-2.
3
Combination locoregional and systemic therapies in hepatocellular carcinoma.肝细胞癌的局部区域与全身联合治疗
Lancet Gastroenterol Hepatol. 2025 Apr;10(4):369-386. doi: 10.1016/S2468-1253(24)00247-4. Epub 2025 Feb 21.
4
Cancer statistics, 2025.2025年癌症统计数据。
CA Cancer J Clin. 2025 Jan-Feb;75(1):10-45. doi: 10.3322/caac.21871. Epub 2025 Jan 16.
5
Abscopal effect in a patient with advanced hepatocellular carcinoma upon resuming bevacizumab in combination with atezolizumab after radiotherapy.贝伐珠单抗联合阿替利珠单抗治疗复发性肝癌伴远隔效应 1 例
Clin J Gastroenterol. 2024 Dec;17(6):1053-1057. doi: 10.1007/s12328-024-02030-w. Epub 2024 Aug 14.
6
Liver resection had better disease-free survival rates compared with radiofrequency ablation in hepatocellular carcinoma: a meta-analysis based on randomized clinical trials.在肝细胞癌中，与射频消融相比，肝切除具有更好的无病生存率：一项基于随机临床试验的荟萃分析。
Int J Surg. 2024 Nov 1;110(11):7225-7233. doi: 10.1097/JS9.0000000000001943.
7
Survival in Patients With Recurrent Intermediate-Stage Hepatocellular Carcinoma: Sorafenib Plus TACE vs TACE Alone Randomized Clinical Trial.索拉非尼联合 TACE 与单纯 TACE 治疗复发性中期肝细胞癌患者的生存：随机临床试验。
JAMA Oncol. 2024 Aug 1;10(8):1047-1054. doi: 10.1001/jamaoncol.2024.1831.
8
Risk versus Benefit of Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.酪氨酸激酶抑制剂治疗肝细胞癌的风险与获益：一项随机对照试验的系统评价和荟萃分析。
Clin Pharmacol Ther. 2024 Aug;116(2):328-345. doi: 10.1002/cpt.3312. Epub 2024 May 27.
9
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update Clinical Insights.晚期肝细胞癌的全身治疗：美国临床肿瘤学会指南更新临床见解。
JCO Oncol Pract. 2024 Aug;20(8):1035-1039. doi: 10.1200/OP.24.00189. Epub 2024 Apr 25.
10
Efficacy of radiofrequency ablation combined with sorafenib for treating liver cancer complicated with portal hypertension and prognostic factors.射频消融联合索拉非尼治疗肝癌合并门静脉高压的疗效及预后因素
World J Gastroenterol. 2024 Mar 21;30(11):1533-1544. doi: 10.3748/wjg.v30.i11.1533.
Zotero 插件